I. Dogan Et Al. , "Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer," CANCER RESEARCH , vol.81, no.4, 2021
Dogan, I. Et Al. 2021. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer. CANCER RESEARCH , vol.81, no.4 .
Dogan, I., Aydin, E., Khanmammadov, N., Aydiner, A., & Saip, P., (2021). Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer. CANCER RESEARCH , vol.81, no.4.
Dogan, İzzet Et Al. "Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer," CANCER RESEARCH , vol.81, no.4, 2021
Dogan, İzzet Et Al. "Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer." CANCER RESEARCH , vol.81, no.4, 2021
Dogan, I. Et Al. (2021) . "Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer." CANCER RESEARCH , vol.81, no.4.
@article{article, author={İzzet DOĞAN Et Al. }, title={Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer}, journal={CANCER RESEARCH}, year=2021}